Sugi Predict

Sugi Predict / Compounds / SCHEMBL2992089

SCHEMBL2992089

SCHEMBL2992089

COc1ccc2cc(OCc3ccccc3)c(N)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.53
▸ ALOX5 P09917 1/20 0.51
▸ ABCB1 P08183 3/20 0.49
▸ HTR1A P08908 1/20 0.49
▸ DRD2 P14416 1/20 0.49
▸ PDGFRB P09619 1/20 0.49
▸ PDGFRA P16234 1/20 0.49
▸ HDAC8 Q9BY41 1/20 0.48
▸ CTSL P07711 1/20 0.47
▸ CTSB P07858 1/20 0.47
▸ MAPT P10636 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ GAA P10253 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30461777 1.00 MAOB (0.53) MAOBALOX5ABCB1HTR1ADRD2
SCHEMBL629661 0.90 ALOX5 (0.65) MAOBALOX5PDGFRBPDGFRAMAPT
SCHEMBL629848 0.90 ALOX5 (0.65) MAOBALOX5PDGFRBPDGFRAMAPT
SCHEMBL7827220 0.87 PDGFRB (0.59) MAOBALOX5ABCB1HTR1ADRD2
SCHEMBL9315251 0.85 MAOB (0.58) MAOBABCB1HTR1ADRD2HDAC8
SCHEMBL3915606 0.85 MAOB (0.58) MAOBABCB1HTR1ADRD2HDAC8
SCHEMBL30189780 0.85 MAOB (0.58) MAOBABCB1HTR1ADRD2HDAC8
SCHEMBL3002216 0.85 ALOX5 (0.55) MAOBALOX5HTR1ADRD2PDGFRB
SCHEMBL29375277 0.85 ALOX5 (0.55) MAOBALOX5HTR1ADRD2PDGFRB
SCHEMBL22412158 0.81 MAOB (0.50) MAOBALOX5MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019236-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2023-01-19 — — US disclosed
CN-114025844-B Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-07-26 — — CN disclosed
CN-114025844-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2022-02-08 — — CN disclosed
EP-3938038-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-01-19 — — EP disclosed
WO-2021127499-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 — — WO disclosed
CN-112955438-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2021-06-11 — — CN disclosed
EP-3810580-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2021-04-28 — — EP disclosed
US-10954202-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2021-03-23 — — US disclosed
US-20210009542-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF ABBVIE INC. 2021-01-14 — — US disclosed
US-10851073-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2020-12-01 — — US disclosed
US-20200299246-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2020-09-24 — — US disclosed
WO-2020186199-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2020-09-17 — — WO disclosed
US-20100197744-A1 Organic Compounds BARNES DAVID 2010-08-05 — — US disclosed
EP-2155704-A1 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS Novartis Ag (CH) 2010-02-24 — — EP disclosed
WO-2008148744-A1 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2008-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197744-A1 Organic Compounds PTPRS, PTPRO, PTPRC MAOB 1739/4885ALOX5 256/4885ABCB1 2918/4885
US-20230019236-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 MAOB 2577/4885ALOX5 4307/4885ABCB1 3405/4885
US-10851073-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof PTPN1, PTPN2, PTPN18 MAOB 2577/4885ALOX5 4307/4885ABCB1 3405/4885
US-10954202-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof PTPN1, PTPN2, PTPN18 MAOB 2577/4885ALOX5 4307/4885ABCB1 3405/4885
US-20210009542-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 MAOB 2577/4885ALOX5 4307/4885ABCB1 3405/4885
US-20200299246-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 MAOB 2577/4885ALOX5 4307/4885ABCB1 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.